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Prechemotherapy subclinical left ventricular dysfunction: Do 
we know the mechanism?
We would like to thank Dr Tadic and colleague for their interest 
in our research manuscript titled "Pediatric Malignancies: Is the 
Pre-chemotherapy Left Ventricular Function Normal?"1 and their 
contribution in the research related to chemotherapy-induced car-
diomyopathy. Tadic et al have recently published their research 
findings of abnormal left ventricular (LV) systolic function in 122 
chemotherapy naïve and radiotherapy naïve cancer patients (pre-
chemotherapy) and 45 age-matched controls. They reported signifi-
cant abnormality in LV systolic function in cancer patients compared 
to controls and reported a decrease in LV global longitudinal strain, 
(19.1 ± 2.1% vs 17.8 ± 3.5%, P - .022), LV global circumferential strain, 
(22.9 ± 3.5% vs 20.1 ± 4.1%, P < .001), and LV global radial strain, 
(40.5 ± 8.8% vs 35.2 ± 10.7%;P - .004).2 These finding are similar to 
findings in our study population where we have found significant ab-
normalities LV systolic function as assessed by speckle strain imag-
ing in prechemotherapy group compared to normal group. However, 
there were no statistical significant differences in LV systolic func-
tion on subgroup analysis of solid vs. hematological tumors.
Finding of LV systolic function in this fragile population even 
before use of chemotherapy is very intriguing. The mechanism of 
the underlying abnormalities in the left ventricular dysfunction, as 
assessed by GLS, in the cancer patients is not completely studied. 
So far the mechanisms of cancer leading to subtle changes in LV sys-
tolic function even before the use of chemotherapy are speculative. 
Several mechanisms have been postulated including the effect of 
anemia, higher inflammatory state, and direct infiltration of myocar-
dium with malignant cells in cancer patients. The effect of anemia on 
LV systolic function and strain was evaluated by Zhou et al in non-
cancer patients. The 39 adult patients with hemoglobin (Hb) 6-9 g/dL 
had abnormal GLS (−18.3 ± 1.8 vs −20.8 ± 2.6 vs −21.4 ± 2.7), abnor-
mal GCS (−18.1 ± 3.7 vs −19.6 ± 4.6 vs −19.8 ± 4.2), higher LV end-di-
astolic volume (115.0 ± 27.4 vs 97.2 ± 29.4 vs 94.9 ± 31.7), higher 
LV end-systolic volume ( 40.2 ± 9.9 vs 36.9 ± 10.1 v. 35.7 ± 12.3), 
and higher LV indexed mass ( 77.4 ± 6.8 vs 73.8 ± 7.9 vs 72.5 ± 8.2) 
as compared those with 44 age-matched adults with Hb >9 g/dL 
and 40 matched healthy volunteers.3 Among our population of pe-
diatric cancer patients, the patients with leukemia had significant 
lower Hb compared to the group with solid tumors (Hb 8.4 ± 3.3, 
11.4 ± 3.6 P < .001*). However, the LVGLS was equally decreased 
in both groups of patients (−19.5 ± 2.4 vs −19.2 ± 2.9, P - .7).1 There 
is another proposed theory of infiltration of the myocardium by cir-
culating cancer cells leading to cardiac dysfunction. Leukemic infil-
trates and hemorrhage were observed in 69% of the 420 hearts in 
an autopsy study of leukemia patients.4 The proposed mechanism of 
heightened inflammatory state in malignancies and association with 
changes in the LV systolic function is not completely understood. In 
an animal study, GLS was decreased in dogs with systemic inflam-
matory response syndrome compared to healthy dogs (−14.6 ± 3.2 
vs − 18.5 ± 4.1; P - .003).5 In a meta-analysis of 8 studies involving 
794 patients, there was a significant association between the worse 
LV function and GLS values and mortality (standard mean difference 
−0.26; 95% CI- 0.47, −0.04, P - .02) in patients with severe sepsis/
and or septic shock. There was no association between LVEF and 
mortality in the same population of patients.6 Therefore, the mecha-
nism leading to prechemotherapy changes in the LV systolic function 
is still elusive.
To study the underlying mechanism of prechemotherapy LV dys-
function in patients with malignancies, larger studies in a prospective 
model designed to evaluate the left ventricular function and their 
correlation with the cardiac biomarkers and biochemical markers of 
inflammation are warranted. This calls for a collaborative effort be-
tween with the cardiologist and the oncologist. As a first step, it is 
important to recognize that prechemotherapy LV systolic dysfunc-
tion exists, which can be detected by the speckle tracking echocar-
diography. As more and more research data are being published, we 
propose adding the speckle echocardiography for assessing the LV 
systolic function in patients even before they have received chemo-
therapy. This may help stratify high-risk patients who are at risk for 
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